COMMUNIQUÉS West-GlobeNewswire

LIXTE Biotechnology Holdings Provides Update on Recent Activities
20/05/2024
Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality” Presentation at MedInvest Biotech and Pharma Investor Conference Co- [...]
ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING
20/05/2024
AGOURA HILLS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its Chief Clinical Officer- Dr. Anthony Maida will be participating at the ASCO 2024 meeting. Abstract: [...]
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease
20/05/2024
SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events. Company advances SNK01 into [...]
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
20/05/2024
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to [...]
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
20/05/2024
Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced precancerous lesion patients [...]
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
20/05/2024
Boston (May 20, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced [...]
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 (florzolotau) for the Diagnosis of Progressive Supranuclear Palsy
20/05/2024
Fast Track Designation follows announcement in January 2024 that the U.S. Food and Drug Administration (FDA) granted a “Study May Proceed” letter for Aprinoia’s planned Phase 3 study of APN-1607 (florzolotau) in the U.S [...]
Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome
20/05/2024
Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X Syndrome SAN DIEGO, May 20, 2024 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical- [...]
InnovAge Welcomes John Koehn as Senior Vice President of External Affairs
20/05/2024
DENVER, May 20, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to dual-eligible seniors through the Program of All- [...]
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
20/05/2024
Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC NEEDHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. ( [...]
PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers
20/05/2024
SALT LAKE CITY, May 20, 2024 (GLOBE NEWSWIRE) -- PolarityTE, a clinical-stage biotechnology company developing regenerative tissue products, today announced that it has raised $12.5 million in equity financing from [...]
Scorpius Holdings Announces Major Expansion in San Antonio with New State-of-the-Art Storage and Testing Facility
20/05/2024
DURHAM, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) , an integrated contract development and manufacturing organization (CDMO), today announced a significant expansion of its [...]
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20/05/2024
SOUTH SAN FRANCISCO, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that the Human Capital Committee of its Board of Directors, which is composed [...]
PetMed Express, Inc. Announces Appointment of Justin Mennen to Board of Directors
20/05/2024
Veteran technology executive brings decades of experience leading digital transformations across large-scale global enterprises DELRAY BEACH, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. , parent company [...]
Intercept Presents New Sub-Analyses of Phase 3 POISE Data Showcasing the Effect of OCA on Key Liver Biomarkers and Fibrosis in Patients with PBC at Digestive Disease Week® 2024
20/05/2024
OCA normalizes levels of ALT and AST, liver biomarkers associated with poor clinical outcomes in a significantly higher proportion of patients after 12 months of treatment compared to placebo; reductions demonstrated as [...]
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
20/05/2024
Four clinical device performance studies successfully demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions and eating schedules SAN DIEGO, May 20, 2024 ( [...]
GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors
20/05/2024
GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with CTLA-4 blockade Researchers from the National Cancer Institute will [...]
Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention
20/05/2024
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- Cerevance , a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced that Craig Thompson, chief executive officer, will [...]
Volta Medical presents results from the first transatlantic randomized controlled trial comparing AI-assisted ablation procedure with the conventional treatment for persistent atrial fibrillation patients
20/05/2024
TAILORED-AF trial findings demonstrated superiority in freedom from atrial fibrillation (AF) with or without anti-arrhythmic drugs at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) [...]

Pages